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Multidrug resistance in bacteria, defined as the ability of a bacterial strain to resist the killing effects of more 
than one antibiotic, represents a major threat to global healthcare. Every year in the United States, two million 
people are infected with a multidrug resistant strain of bacteria. According to the Center for Disease Control 
(CDC), out of those two million people, about 35,000 will die from their infection. Thus, these multidrug 
resistant diseases are considered by the CDC to be the most dangerous diseases in the world. While multidrug 
resistance can occur through several different mechanisms, a major contributor to multidrug resistance are 
the bacterial efflux pumps. Efflux pumps are transporters that reside in the membrane of a bacterial cell, and 
they function by pumping out toxic organic compounds, including antibiotics, from the cell. These efflux 
pumps often lack specificity for the compounds that they can expel from the cell which means that a single 
type of efflux pump can confer resistance to many types of antibiotics all at once. When bacterial cells 
produce high levels of these efflux pumps in their membranes, it can give rise to a multidrug resistance 
characteristic. I intend to inhibit the efflux pump using single-stranded DNA aptamers. These aptamers 
should either clog the pump opening and/or bind to the Tol C region of the pump, making it inactive. This 
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Societal Importance  
Multi-drug resistant bacterial infections represent a significant threat to our public 
healthcare system. According to the CDC, about 2.8 million people in the United States 
get an antibiotic resistant infection each year. Over 35,000 people will die per year from 
an infection that will not respond to antibiotics.1 The rise of antibiotic-resistant strains of 
bacteria can be attributed to several causes, such as the overuse of antibiotics in livestock 
and the prescription of antibiotics to treat illnesses that cannot be treated with antibiotics 
(this includes most viral infections). Patient compliance is also a problem. Some 
individuals who are prescribed antibiotics do not finish the entire antibiotic regimen or hold 
back some of their prescribed antibiotics and take them at a later occasion when they are 
sick but have not received a proper medical diagnosis.2 When this occurs, it allows for the 
most resistant bacteria to persist. After many decades of these practices, we are now faced 
with greater numbers of antibiotic-resistant strains of bacteria that our existing antibiotics 
cannot kill, and this has led to higher mortality rates from infections.  
Multidrug Resistance  
While there are several ways that bacteria can become multidrug resistant, one 
common mechanism is through the use of bacterial efflux pumps. The efflux pump is a 
transporter that is located in the membrane of the bacterial cell and it gives a bacterium the 
ability to export toxins from the cell. While efflux pumps are common to many types of 
bacteria, they tend to be found at higher levels in the membranes of multidrug resistant 
strains.3 Bacterial efflux pumps tend to be nonspecific with respect to the compounds that 
they can export which means that bacteria that overexpress them can resist the killing 
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effects of many different types of antibiotics. The ESKAPE pathogens in particular are 
known to utilize their efflux pumps to become multidrug resistant.4 The ESKAPE 
pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) cause over 
two million illnesses and kill about 23,000 people a year. According to the CDC, these 
pathogens are the leading cause of multidrug resistant infections occurring in the world.5      
Bacterial Efflux Pump 
There are many different families of the efflux pump that bacteria can utilize to 
become antibiotic resistant. The different families are ATP-binding cassette (ABC), major 
facilitator superfamily (MFS), multidrug and toxin extrusion (MATE), small multidrug 
resistance (SMR), and resistance-nodulation-cell division (RND) families. Each family 







Figure 1. Bacterial efflux pump families. Each family of efflux differs with structure, 
mechanism, and placement within the cell membrane.6 
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The ABC transporter directly uses ATP as energy to function, while the other 
families use electrochemical gradients as their energy source. The structure of the ABC 
transporter has transmembrane domains (TMDs) that have substrate binding sites and 
nucleotide-binding domains (NBDs) that the ATP will bind to and be hydrolyzed. The MFS 
transporter is the most diverse family of transporters. They consist of uniporters, 
symporters, and antiporters. The structure of the transporter includes two domains. To 
pump substrates out, they must go through two conformational switches from inward-open 
to outward-open. The MATE transporter structure has amino-terminal and carboxy-
terminal domains related by pseudo-twofold symmetry that form a V-shaped central cavity 
open to the extracellular space. The mechanism uses hydrogen ions and sodium gradients 
to efflux out substrates. The SMR transporters are small and have four transmembrane 
helices that function as dimers. During the transport process, the pump has two 
conformations to efflux substrates. The conformations are the inward-facing and outward-
facing states.6 The RND efflux pump goes through three different conformations to bind 
substrates and efflux them. The AcrAB-TolC and MexAB-OprM are multidrug efflux 
pumps that belonging to the RND superfamily and are the two most common types of 
pumps.7 
 The RND AcrAB-TolC efflux pump is composed of three different components. It 
is made up of an inner membrane transporter (AcrB), an adaptor protein (AcrA), and an 
outer membrane channel (TolC). AcrA is found within the periplasm of the cell and it holds 
AcrB and TolC together. AcrB is found within the inner membrane of the cell. TolC is 
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found within the outer membrane. Once the protein components are assembled, they make 
a transporter system that spans from the cytoplasm to the outside of the cell (Figure 2).6 
Figure 2. RND bacterial efflux pump showing how AcrA, AcrB, and TolC interact with 
one another in the intact efflux pump. Molecules can be pumped out of the cell through 
this efflux pump either from the cytoplasm or from the periplasm. Structural model 
generated from PDB ID 5O66. 
The AcrB portion of the efflux pump is the active portion of the efflux pump. AcrB 
is a trimer of 1,049 amino acids. It is made up of an extra-membrane headpiece and a 
transmembrane region. The three transmembrane domain is arranged like a ring with a 
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central hole. The hole crosses the membrane and connects to the bottom of the headpiece. 
When looking at AcrB from a side view, the head piece and the transmembrane portion are 
visible (Figure 3).8 This is the portion of the efflux pump that is thought to be responsible 
for expelling antibiotics from the cell. 
  
 
Figure 3. Side view of the AcrB portion of the pump. The funnel portion is seen at the top 
of the pump.8 
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The AcrB region is what allows for the large variety of substrates to be expelled. 
AcrB has three different conformations which allows for the expelling of different 
antibiotics. The first step is known as the access state and the vestibule opens to the 
periplasm. This is where substrates can enter the vestibule, but the binding site is too small 
for any substrate to bind to it. In the binding state, the vestibule remains open, and the 
binding site expands enough for the substrate to bind to it. The substrates will bind to 
multiple locations in the aromatic pocket inside the vestibule. The exit from the binding 
site is blocked off so no substrate can get out. During the extrusion state the vestibule is 
closed and the exit finally opens. The substrate is then pushed into the funnel portion due 
to the binding site shrinking and expelling the substrate out into TolC (Figure 4). These 
processes are fueled by the proton motive force.9 
 
Figure 4. Birds-eye view of the AcrB mechanism. The funnel is shown where the antibiotic 
will be pushed through. After exiting the funnel, the antibiotic would leave the cell through 
the TolC channel.9 
The TolC portion of the efflux pump is a trimer with 428 amino acids. The 
appearance of the trimer looks like a hollow cylinder (Figure 5). The pump is split into β-
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domain, an α- helical domain, and a mixed α/β-domain. The top portion of the structure is 
viewed to be open, and the bottom portion of the structure is tapered closed.10 
 
 
Figure 5. Cross-section of the interior of TolC. It is a hollow cylinder-like structure acting 
as a channel.10 
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TolC has an important role in the export of substrates. During transport it is open 
so substrates can fit through the channel. The opening mechanism includes the inner pair 
of coils rotating around the pair next to it to dilate the entrance. The structural repeat of the 
TolC portion allows for the channel to open. Figure 6 shows the different conformations 
of TolC from a bird’s eye view. The mechanism of the TolC tunnel was proposed to 
facilitate the first passage of substrates across two membranes.10 The assumption was made 
that the substrates follow their concentration gradient to the outside of the cell. The closing 
of the pump also ensures there is only one way out for the substrates to go. 
Figure 6. Open and closed conformations of TolC. A) The closed conformation. B) The 
open conformation.10 
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 With the mechanisms of AcrB and TolC put together it allows for the substrate to 
be effectively pumped from the bacterial cell. The figure below shows the efflux pump 
assembled with the functional mechanisms to efflux out substrates. The overall pathway of 
the substrates is to bind to AcrB and be actively pumped into TolC. Once in TolC the 
substrates can then follow their concentration gradient outside the cell (Figure 7).  
Figure 7. The mechanism of the bacterial efflux pump.9 
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Given the importance of bacterial efflux pumps in conferring multi-drug resistance 
upon bacteria that overexpress them, many researchers have sought to identify inhibitors 
of efflux pumps to counter multidrug resistance.11 Many researchers have investigated 
inhibiting the bacterial efflux pump. Some compounds that have been evaluated are both 
plant extracts and polyclonal antibodies.12,13,14 There has been evidence that there are 
compounds that have an inhibitory effect on this pump.  
Objective and Related Work  
The goal of my research is to develop nucleic acid aptamers that will bind to and 
inhibit bacterial efflux pumps that, when functional, give bacterial cells the ability to 
survive in the presence of antibiotics. By blocking the activity of bacterial efflux pumps, 
these nucleic acid aptamers will prevent bacterial cells from developing resistance to the 
antibiotics that we use to treat infections. 
Questions to be addressed: 
1. Can we develop single-stranded DNA aptamers that will bind to the outer opening 
of the TolC component of bacterial efflux pumps? 
2. Will single-stranded DNA aptamers that bind to the efflux pump block the export 
of antibiotics through the pump and will this increase the susceptibility of the 
bacteria to antibiotics? 
Given the role that this efflux pump plays in exporting antibiotics from the cell, we 
intend to develop single-stranded DNAs that will bind to the outer opening of the pump 
and block its function. There is precedence in the literature that this approach can work. 
Researchers have found that antibodies that bind specifically to the TolC portion of the 
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pump can sensitize the cells to antibiotics that the cells otherwise were able to tolerate.14 
This research shows that macromolecules that bind to TolC can influence bacterial 
susceptibility to antibiotics. I am hopeful that single-stranded DNA aptamers that bind to 
TolC will have the same effect as the TolC antibodies, but with the added advantage that 
single-stranded DNA aptamers are cheap and easy to synthesize in large quantities while 
antibodies are not. 
Methods and Expectations  
I will develop single-stranded DNA aptamers that can bind to the bacterial efflux 
pump through a process known as cell-SELEX. Cell-SELEX is a procedure for selecting 
molecules that have desired properties from a large and diverse set of starting molecules. 
The desired molecules are then amplified and passed through more selection processes to 
result in a final population of molecules that in this case will have a strong binding affinity 
for the outer portion of the efflux pump in the live cells. 
My Cell-SELEX procedure will use live E. coli cells that overexpress the AcrA-
AcrB-TolC efflux pump. A mixed population of aptamers with many different DNA 
sequences (~1015 different sequences) will be added to the cells and incubated for 30 
minutes. This will give a chance for any aptamers that happen to have a structure that lends 
itself to binding to TolC to do so. Following the incubation period, the cells will be 
collected and the solution that contains the non-bound aptamers will be discarded. The cells 
will be heated to release the bound aptamers. The collected aptamers will then be incubated 
with cells that do not express the TolC component of efflux pump. This step represents a 
negative selection step, and it will allow me to select for more specific binding between 
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the aptamers and TolC. Aptamers that pass these selection steps will be passed on through 
additional rounds of Cell-SELEX (Figure 8) to gradually select for the strongest binders. 
  
Figure 8. Cell-SELEX procedure.15 Multiple rounds of Cell-SELEX will be performed. 
After many rounds of Cell-SELEX has been performed, I will use growth curves to 
examine the effects that the aptamer pools have on antibiotic susceptibility in live cells. 
For each pool of aptamers, I will measure cell growth in the presence and absence of 
antibiotics and aptamers and compare them with the growth characteristics of cells grown 
with neither antibiotics nor aptamers present. This will allow me to determine if the 
aptamers have an inhibiting effect on the efflux pump. By comparing the different growth 
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curves to the control groups, it will allow me to measure the efflux pump inhibitory activity 
of the aptamers (Figure 9). 
 
  
Figure 9. Hypothetical growth curve comparing cells grown with only aptamers, cells 
grown with just antibiotics, and cells grown with antibiotics and aptamers. Here, the 
presence of the aptamers enhances the killing effects of the antibiotics. 
Once the pools of aptamers have been identified for having activity, I will 
determine which aptamer pool has the most activity and further my investigation on that 
pool. The aptamers will be cloned using standard molecular cloning techniques and their 
specific nucleotide sequences will be determined by conducting DNA sequencing. Once I 
have identified the specific nucleotide sequence of the active aptamers, I will purchase 
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synthetic versions of the aptamers from commercial sources that specialize in custom DNA 
synthesis. The synthetic aptamers will be tested for their potency against a broad panel of 
antibiotics and in several strains of bacteria including both Gram-positive and Gram-
negative strains. This will allow me to determine the species specificity of the aptamers. I 
hypothesize that aptamers that have been selected in cell-SELEX using E. coli will show 
greatest activity against E. coli and related bacteria and that they will be less active against 
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